Literature DB >> 8191204

Effect of inhaled 3% CO2 on Cheyne-Stokes respiration in congestive heart failure.

R D Steens1, T W Millar, X Su, D Biberdorf, P Buckle, M Ahmed, M H Kryger.   

Abstract

Cheyne-Stokes respiration (CSR) in severe stable congestive heart failure (CHF) may be associated with significant nocturnal arterial oxygen desaturation and sleep disruption. Previous investigations of inhaled CO2 in CSR have been uncontrolled and of short duration, sleep has not been monitored electroencephalographically, and most patients studied have had neurological disease with or without cardiac disease. The purpose of our study was to document the effects of inhaled CO2 on CSR in patients with severe stable CHF (left ventricular ejection fraction < 35% and NYHA class 3 or 4 dyspnea) in controlled all-night polysomnographic studies. Six patients were studied for 3 nights and days: adaptation, control and inhalation of CO2. These patients received a constant F1CO2 = 0.03 in air (with a 4-5 mm Hg increase in PaCO2) on night 3. This caused virtual abolition of CSR as reflected by CSR duration/total sleep time (62-2.2%; p = 0.0012) and CSR duration/nonrapid eye movement (NREM) sleep time (73-2.4%; p = 0.00064), and NREM apnea index was reduced from 33.5 to zero (p = 0.026). The apparatus used to accurately control F1CO2, however, was intrusive and some features of sleep structure such as sleep latency were adversely affected. We conclude that inhalation of CO2 with a constant F1CO2 = 0.03 virtually eradicates CSR in all-night polysomnographically monitored studies in patients with severe stable CHF. The clinical significance of these findings remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191204     DOI: 10.1093/sleep/17.1.61

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  26 in total

Review 1.  Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure.

Authors:  M T Naughton
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

2.  Persistent hypersomnolence in an elderly male.

Authors:  Rahul K Kakkar
Journal:  J Clin Sleep Med       Date:  2007-04-15       Impact factor: 4.062

Review 3.  Pathophysiology and treatment of Cheyne-Stokes respiration.

Authors:  M T Naughton
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

Review 4.  Epidemiology of Sleep-Disordered Breathing and Heart Failure: What Drives What.

Authors:  Sushma M Dharia; Lee K Brown
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 5.  Dynamic CO₂ inhalation: a novel treatment for CSR-CSA associated with CHF.

Authors:  Zhi Hui Wan; Fang Jing Wen; Ke Hu
Journal:  Sleep Breath       Date:  2012-05-24       Impact factor: 2.816

Review 6.  The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses.

Authors:  R Nisha Aurora; Susmita Chowdhuri; Kannan Ramar; Sabin R Bista; Kenneth R Casey; Carin I Lamm; David A Kristo; Jorge M Mallea; James A Rowley; Rochelle S Zak; Sharon L Tracy
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

Review 7.  Exercise oscillatory ventilation: Mechanisms and prognostic significance.

Authors:  Bishnu P Dhakal; Gregory D Lewis
Journal:  World J Cardiol       Date:  2016-03-26

Review 8.  Cheyne-stokes respiration in patients with heart failure.

Authors:  Laila AlDabal; Ahmed S BaHammam
Journal:  Lung       Date:  2009-12-03       Impact factor: 2.584

9.  Treatment of central sleep apnea in U.S. veterans.

Authors:  Susmita Chowdhuri; Ahmed Ghabsha; Prabhat Sinha; Medina Kadri; Simranjit Narula; M Safwan Badr
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

10.  Dynamic CO2 therapy in periodic breathing: a modeling study to determine optimal timing and dosage regimes.

Authors:  Yoseph Mebrate; Keith Willson; Charlotte H Manisty; Resham Baruah; Jamil Mayet; Alun D Hughes; Kim H Parker; Darrel P Francis
Journal:  J Appl Physiol (1985)       Date:  2009-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.